Author: admin als-handoff

Donnelly brings more than 25 years of biopharmaceutical expertise in CMC and regulatory operations.  SEATTLE and VANCOUVER, British Columbia, September 18, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced…

SEATTLE and VANCOUVER, British Columbia, September 11, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced Mark Rubinstein, M.D., will assume the role of Interim Chief Medical Officer (CMO). Dr….

Filing based on pivotal Phase 3 ORCA-2 and ORCA-3 clinical trials demonstrating statistically significant and clinically meaningful smoking cessation. FDA acceptance starts the review process and sets timing for potentially the first new FDA-approved pharmacotherapy in two decades. PDUFA targeted date set for June 20, 2026. SEATTLE and VANCOUVER, British Columbia, September 3, 2025 (GLOBE…

SEATTLE and VANCOUVER, British Columbia, Sept. 2, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that Rick Stewart, CEO of Achieve Life Sciences, will be participating at two…

Conference Call Scheduled for 8:30 AM EDT Today, August 7, 2025. SEATTLE and VANCOUVER, British Columbia, August 7, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial…